Deregulated Fcγ receptor expression in patients with CIDP.

Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics (2016) 0.82

Interobserver agreement for the assessment of handicap in stroke patients. Stroke (1988) 20.14

Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34

Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 8.13

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 3.59

Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity (2000) 3.55

Roles of Fc receptors in autoimmunity. Nat Rev Immunol (2002) 2.96

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity (2003) 2.20

Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2001) 1.88

Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med (2006) 1.81

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve (2000) 1.65

Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med (2008) 1.43

Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet (2005) 1.38

Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol (2011) 1.38

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry (1993) 1.28

A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. II. Differential binding of GATA4 and Yin-Yang1 transcription factors and correlated receptor expression and function. J Immunol (2004) 1.19

From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol (2007) 1.14

Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology (2002) 1.06

Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol (2000) 0.96

Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol (2008) 0.96

Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha. J Neurol Neurosurg Psychiatry (1998) 0.94

Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol (2010) 0.92

Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Ann Oncol (2000) 0.91

The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the -343 G -> C polymorphism associated with systemic lupus erythematosus. J Biol Chem (2006) 0.91

Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology (2007) 0.90

Activation of Fc gamma RI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses. J Immunol (2009) 0.90

pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst (2009) 0.88

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Intern Med (2009) 0.85

Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy. Intern Med (2009) 0.80

Monocyte CD64 expression as a novel biomarker for the disease activity of systemic lupus erythematosus. Lupus (2015) 0.78

Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon α-2b: a neuropathology case report. Intern Med (2012) 0.76